Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.73 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.73 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | DPP4 | P27487 | 2/20 | 0.43 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.43 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | VNN1 | O95497 | 1/20 | 0.37 |
| ▸ | ACE | P12821 | 1/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2876578 | 1.00 | POLB (0.73) | POLBL3MBTL1MEN1KMT2ADPP4 | |
| SCHEMBL37939 | 1.00 | POLB (0.73) | POLBL3MBTL1MEN1KMT2ADPP4 | |
| SCHEMBL2679258 | 0.94 | L3MBTL1 (0.64) | POLBL3MBTL1MEN1KMT2ADPP4 | |
| SCHEMBL1857058 | 0.94 | L3MBTL1 (0.64) | POLBL3MBTL1MEN1KMT2ADPP4 | |
| SCHEMBL2904191 | 0.94 | L3MBTL1 (0.64) | POLBL3MBTL1MEN1KMT2ADPP4 | |
| SCHEMBL23533074 | 0.92 | L3MBTL1 (0.62) | POLBL3MBTL1MEN1KMT2ADPP4 | |
| SCHEMBL15515007 | 0.86 | — | — | |
| SCHEMBL2566249 | 0.86 | — | — | |
| SCHEMBL2568389 | 0.86 | — | — | |
| SCHEMBL18426199 | 0.85 | POLB (0.59) | POLBL3MBTL1MEN1KMT2ADPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 394 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150025056-A1 | SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES | INCYTE CORPORATION (US) | 2015-01-22 | — | — | US | claimed |
| US-8426441-B2 | Inhibitors of bruton's tyrosine kinase | ROCHE PALO ALTO LLC (US) | 2013-04-23 | — | — | US | claimed |
| EP-2264030-A1 | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases | Incyte Corporation (US) | 2010-12-22 | — | — | EP | claimed |
| EP-1694410-B1 | CYCLOPROPANE DERIVATIVES AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC (JP) | 2010-04-14 | — | — | EP | claimed |
| US-20090186898-A1 | Inhibitors of bruton's tyrosine kinase | ROCHE PALO ALTO LLC | 2009-07-23 | — | — | US | claimed |
| US-20080167288-A1 | Substituted cyclic hydroxamates as lnhibitors of matrix metalloproteinases | LNCYTE CORPORATION (US) | 2008-07-10 | — | — | US | claimed |
| US-20050113344-A1 | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases | INCYTE CORPORATION | 2005-05-26 | — | — | US | claimed |
| US-20040142999-A1 | Novel compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2004-07-22 | — | — | US | claimed |
| US-20260076960-A1 | METAP2 INHIBITORS AND METHODS OF TREATING OBESITY | SYNDEVRX INC (US) | 2026-03-19 | — | — | US | disclosed |
| US-20250288606-A1 | POLYMER-CONJUGATED METAP2 INHIBITORS, AND THERAPEUTIC METHODS OF USE THEREOF | SYNDEVRX, INC. | 2025-09-18 | — | — | US | disclosed |
| EP-3858385-B1 | POLYMER-CONJUGATED METAP2 INHIBITORS, AND THERAPEUTIC METHODS OF USE THEREOF | SYNDEVRX INC (US) | 2024-09-11 | — | — | EP | disclosed |
| US-12043632-B2 | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors | AJAX THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-20240199648-A1 | MAP4K1 INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2024-06-20 | — | — | US | disclosed |
| CN-118201928-A | 6-Heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors | 艾捷斯治疗公司 | 2024-06-14 | — | — | CN | disclosed |
| EP-0486727-A2 | Microbial reduction of benzazepine and benzothiazepine derivatives | E.R. SQUIBB & SONS, INC. (US) | 1992-05-27 | — | — | EP | disclosed |
| US-5036066-A | Muscle relaxants, anxiolytic agents, anticonvulsants | HOFFMANN-LA ROCHE INC. (US) | 1991-07-30 | — | — | US | disclosed |
| US-5001142-A | Alzheimer's disease | AMERICAN CYANAMID COMPANY (US) | 1991-03-19 | — | — | US | disclosed |
| EP-0408879-A2 | 1-Substituted-2-(3-amino-1-propynyl)-pyrrolidine derivatives | AMERICAN CYANAMID COMPANY (US) | 1991-01-23 | — | — | EP | disclosed |
| US-4889848-A | 4-OXO-4H-BENZO(A)QUINOLIZINES; MUSCLE RELAXANTS; SEDATIVES; ANTICONVULSANTS; ANXIOLYTIC AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1989-12-26 | — | — | US | disclosed |
| US-4735940-A | Tricyclic pyridine derivatives and pharmaceutical compositions | HOFFMANN-LA ROCHE INC. (US) | 1988-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186898-A1 | Inhibitors of bruton's tyrosine kinase | BTK, SYK, LYN | POLB 1495/4885L3MBTL1 3419/4885MEN1 4752/4885 |
| US-20260076960-A1 | METAP2 INHIBITORS AND METHODS OF TREATING OBESITY | METAP2, METAP1, LNPEP | POLB 4512/4885L3MBTL1 520/4885MEN1 1628/4885 |
| US-20240199648-A1 | MAP4K1 INHIBITORS | MAP4K1, MAP4K4, MAP4K2 | POLB 2761/4885L3MBTL1 2440/4885MEN1 1249/4885 |
| US-12043632-B2 | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors | JAK2, JAK3, STAT5B | POLB 1228/4885L3MBTL1 1749/4885MEN1 3963/4885 |
| US-20150025056-A1 | SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES | MMP25, MMP2, MMP14 | POLB 1479/4885L3MBTL1 3117/4885MEN1 3168/4885 |
| US-20250288606-A1 | POLYMER-CONJUGATED METAP2 INHIBITORS, AND THERAPEUTIC METHODS OF USE THEREOF | METAP2, MTX2, METAP1 | POLB 1365/4885L3MBTL1 1118/4885MEN1 160/4885 |
| US-20080167288-A1 | Substituted cyclic hydroxamates as lnhibitors of matrix metalloproteinases | MMP25, MMP9, MMP24 | POLB 2157/4885L3MBTL1 2118/4885MEN1 3782/4885 |
| US-20050113344-A1 | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases | MMP25, MMP2, MMP14 | POLB 1479/4885L3MBTL1 3117/4885MEN1 3168/4885 |
| US-20040142999-A1 | Novel compounds and compositions as cathepsin inhibitors | CTSS, CTSB, CTSE | POLB 2141/4885L3MBTL1 4113/4885MEN1 4485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.